慢性肝病合并骨质疏松症的影响因素分析

肝脏 ›› 2025, Vol. 30 ›› Issue (11): 1561-1567.

慢性肝病合并骨质疏松症的影响因素分析

敬进华, 马超, 李玉玉, 宁忠慧, 窦婧, 王晓波, 丁国宁, 王晓忠, 郭峰

831100 昌吉回族自治州新疆昌吉回族自治州中医医院内四科(敬进华,丁国宁);830000 乌鲁木齐新疆医科大学第四临床医学院(马超,李玉玉);830000 乌鲁木齐新疆维吾尔自治区中医医院肝病科(宁忠慧,窦婧,王晓波,王晓忠,郭峰)

收稿日期:2024-09-02 出版日期:2025-11-30 发布日期:2026-02-09
通讯作者: 郭峰,Email:gf_sj@163.com
作者简介:共同第一作者:马超

Analysis of influencing factors in patients with chronic liver disease complicated with osteoporosis

JING Jin-hua¹, MA Chao², LI Yu-yu², NING Zhong-hui³, DOU Jing³, WANG Xiao-bo³, DING Guo-ning¹, WANG Xiao-zhong³, GUO Feng³

1. Internal Medicine Ward 4, Xinjiang Changji Hui Autonomous Prefecture Hospital of Traditional Chinese Medicine, Changji Hui Autonomous Prefecture 831100, China;
2. Fourth Affiliated Hospital of Xinjiang Medical University, Urumqi 830000, China;
3. Department of Hepatology, Xinjiang Urumqi Autonomous Region Traditional Chinese Medicine Hospital, Urumqi 830000, China

Received:2024-09-02 Online:2025-11-30 Published:2026-02-09
Contact: GUO Feng,Email:gf_sj@163.com

摘要/Abstract

摘要： 目的分析慢性肝病患者合并骨质疏松症的影响因素。方法回顾性收集2023年9月至2024年6月新疆维吾尔自治区中医医院和新疆昌吉回族自治州中医医院门诊及住院肝病患者215例,采集所有患者人口学信息、血清学指标、营养风险等临床资料,计算CTP评分、MELD评分并将患者分为骨质疏松组和非骨质疏松组,进一步采用多因素logistic回归分析法筛选慢性肝病患者合并骨质疏松症发生的影响因素。结果慢性肝病患者合并骨质疏松症的患病率为22.3％。慢性肝病病因中,慢性乙型病毒性肝炎、原发性胆汁性胆管炎、自身免疫性肝炎和其他病因比较,差异有统计学意义(P<0.05)。两组患者的年龄、BMI比较差异有统计学意义(P<0.05)。在血清学指标中,两组患者ALP、Alb、DBil、TBA、ChE、BUN、Cys-C、β2-MG、血清钙和MELD评分比较,差异有统计学意义(P<0.05)。营养风险评估中,两组患者营养评分、营养风险差异均有统计学意义(P<0.05)。多因素logistic回归分析结果显示:营养风险(OR=1.934, 95%CI :1.264~2.959, P=0.002)和年龄(OR=1.074, 95%CI: 1.031~1.120, P=0.001)是慢性肝病合并骨质疏松症患者的危险因素。结论营养风险和年龄是慢性肝病患者合并骨质疏松的危险因素。

关键词: 慢性肝病, 骨质疏松症, 营养风险, 影响因素

Abstract: Objective To analyze the influencing factors of osteoporosis in patients with chronic liver disease. Methods This study retrospectively collected 215 outpatients and inpatients with liver diseases from the Xinjiang Urumqi Autonomous Region Hospital of Traditional Chinese Medicine and the Xinjiang Changji Hui Autonomous Prefecture Hospital of Traditional Chinese Medicine between September 2023 and June 2024. The clinical data, such as demographic information, serological indexes and nutritional risk, were collected to calculate CTP score and MELD. Patients were divided into osteoporosis group and non-osteoporosis group. Furthermore, multivariate logistic regression analysis was used to screen the risk factors of osteoporosis in patients with chronic liver disease. Results The prevalence of osteoporosis in patients with chronic liver disease was 22.3% . Among the causes of chronic liver disease, chronic hepatitis, primary cholangitis, autoimmune hepatitis and other causes were significantly different between two groups(P<0.05) . There were significant differences between the two groups in age, BMI (P<0.05) , ALP, Alb, DBil , TBA, ChE, BUN, Cys-c,β2-MG, serum calcium and MELD (P<0.05) . In nutrition risk assessment, there were significant differences in nutrition score and nutrition risk (P<0.05) . Multivariate Logistic regression analysis showed that nutritional risk (OR=1.934,95%CI:1.264~2.959 , P=0.002)and age(OR=1.074,95%CI:1.031~1.120, P=0.001 )were risk factors of osteoporosis in patients with chronic liver disease. Conclusion Nutritional risk and age are risk factors of osteoporosis in patients with chronic liver disease.

Key words: Chronic liver disease, Osteoporosis, Nutrition risks, Influencing factors

敬进华, 马超, 李玉玉, 宁忠慧, 窦婧, 王晓波, 丁国宁, 王晓忠, 郭峰. 慢性肝病合并骨质疏松症的影响因素分析[J]. 肝脏, 2025, 30(11): 1561-1567.

JING Jin-hua, MA Chao, LI Yu-yu, NING Zhong-hui, DOU Jing, WANG Xiao-bo, DING Guo-ning, WANG Xiao-zhong, GUO Feng. Analysis of influencing factors in patients with chronic liver disease complicated with osteoporosis[J]. Chinese Hepatolgy, 2025, 30(11): 1561-1567.

/ 推荐

参考文献

[1] 周丽智,黄鑫,唐兰燕,等. 肝性骨病发病机制的研究进展[J]. 中南医学科学杂志,2022,50(4):614-617.
[2] Núria, Guañabens, Albert, et al. Osteoporosis in chronic liver disease[J]. Liver Int, 2018,38(5):776-785.
[3] Peng Y, Xi S, Huang R. Association between hepatitis B virus infection and risk of osteoporosis:a systematic review and meta-analysis[J]. Asian J Surg,2023, 46(10):4598-4600.
[4] Ehnert S, Aspera-Werz R H, Ruoß M, et al. Hepatic osteodystrophy-molecular mechanisms proposed to favor its development[J]. Int J Mol Sci,2019,20(10): 2555.
[5] Ebeling P R, Nguyen H H, Aleksova J, et al. Secondary osteoporosis[J]. Endocr Rev,2022,43(2):240-313.
[6] 中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 实用肝脏病杂志,2023,26(3):后插1-后插22.
[7] 中华医学会肝病学分会,中华医学会感染病学分会. 丙型肝炎防治指南(2022年版)[J]. 中华肝脏病杂志,2022,30(12):1332-1348.
[8] 中华医学会肝病学分会. 原发性胆汁性胆管炎的诊断和治疗指南(2021)[J]. 中华肝脏病杂志,2022,30(3):264-275.
[9] 中华医学会肝病学分会. 自身免疫性肝炎诊断和治疗指南(2021)[J]. 中华肝脏病杂志,2022,30(5):482-492.
[10] 中国中西医结合学会,中华中医药学会,中华医学会,等. 肝硬化中西医结合诊疗指南[J]. 临床肝胆病杂志,2023,39(11):2543-2549.
[11] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会. 酒精性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志,2018,34(5):939-946.
[12] 中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2022)[J]. 中华骨质疏松和骨矿盐疾病杂志,2022,15(6):573-611.
[13] Lee H S, Choi G H, Joo D J, et al. Prognostic value of model for end-stage liver disease scores in patients with fulminant hepatic failure[J]. Transplant Proc,2013, 45(8):2992-2994.
[14] 周新兰,马鑫,王雁冰,等. APRI、FIB-4和GPR对慢性乙型肝炎肝脏炎症程度的诊断价值[J]. 临床肝胆病杂志,2021,37(9):2066-2070.
[15] 中华医学会肠外肠内营养学分会,营养风险-不足-支持-结局-成本/效果多中心协作组,张献娜,等. 营养风险筛查和全球(营养)领导人发起的营养不良诊断(GLIM)第二、三步流程(共识2020)[J]. 中华临床营养杂志,2020,28(4):193-200.
[16] Wang L, Yu W, Yin X, et al. Prevalence of osteoporosis and fracture in China: the China osteoporosis prevalence study[J]. JAMA Netw Open,2021,4(8): e2121106.
[17] Wong W J, Emdin C, Bick A G, et al. Clonal haematopoiesis and risk of chronic liver disease[J]. Nature,2023,616(7958):747-754.
[18] Muratori L, Lohse A W, Lenzi M. Diagnosis and management of autoimmune hepatitis[J]. BMJ,2023,380:e070201.
[19] Lonele C M, Turcu-Stiolica A, Subtirelu M S, et al. Osteoporosis assessment among adults with liver cirrhosis[J]. J Clin Med,2022,12(1):153.
[20] Kobayashi K, Imagama S, Ando K, et al. Epidemiology and effect on physical function of osteosarcopenia in community-dwelling elderly people in Japan[J]. Mod Rheumatol,2020,30(3):592-597.
[21] Park K S, Lee G Y, Seo Y M, et al. Disability,frailty and depression in the community-dwelling older adults with Osteosarcopenia[J]. BMC Geriatr,2021,21 (1):69.
[22] Yang Y J, Kim D J. An overview of the molecular mechanisms contributing to musculoskeletal disorders in chronic liver disease:osteoporosis,sarcopenia, and osteoporotic sarcopenia[J]. Int J Mol Sci,2021,22(5):2604.
[23] 王君,朱志军,曲伟,等. 成人慢性肝病患者肝移植前的骨质疏松症风险评估[J]. 临床和实验医学杂志,2019,18(20):2186-2190.
[24] Oh H, Jun D W, Lee I H, et al. Increasing comorbidities in a South Korea insured population-based cohort of patients with chronic hepatitis B[J]. Aliment Pharmacol Ther,2020,52(2):371-381.
[25] Olmos-Martínez J M, Hernández J L, Fábrega E, et al. Bone mineral density and trabecular bone score in treatment-naïve patients with non-cirrhotic hepatitis C virus infection[J]. Arch Osteoporos,2020,15(1):72.
[26] Lonele C M, Turcu-Stiolica A, Subtirelu M S, et al. A systematic review and meta-analysis on metabolic bone disease in patients with primary sclerosing cholangitis[J]. J Clin Med,2022,11(13):3807.
[27] Ciardullo S, Perseghin G. Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes[J]. Metabolism,2021, 121:154752.
[28] Hejazi J, Davoodi A, Khosravi M, et al. Nutrition and osteoporosis prevention and treatment. Biomed Res Ther,2020,7, 3709-3720.
[29] Jiang B C, Villareal D T. Weight loss-induced reduction of bone mineral density in older adults with obesity[J]. J Nutr Gerontol Geriatr,2019,38(1):100-114.
[30] Fahimfar N, Noorali S, Yousefi S, et al. Prevalence of osteoporosis among the elderly population of Iran[J]. Arch Osteoporos,2021,16(1):16.